EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cascade Mono- and Di-Functionalization of Anticancer Diastereomeric Benzoxazole-Ansamycins toward the Development of Highly Potent Hsp90 Inhibitors of Decreased Toxicity in Normal Cells

Aleksandra Leśniewska iD, Adam Buczkowski iD, Piotr Ruszkowski, Matthew J Binder iD, Alison D Axtman iD, Wojciech Schilf, Ewelina Smolarz iD, Krystian Pyta iD, Maria Gdaniec iD, Franz J Bartl, Piotr Przybylski iD

Journal of Medicinal Chemistry · 12.11.2026 · 69 (21) · 25151-25180

DOI: 10.1021/acs.jmedchem.6c00563 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 18.10.2026. Verfasst von Aleksandra Leśniewska und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Chemistry, Adam Mickiewicz University, Uniwersytetu Poznanskiego 8, 61-614Poznan, Poland. Hauptthemen laut MEDLINE: HSP90 Heat-Shock Proteins, Antineoplastic Agents, Benzoxazoles, Lactams, Macrocyclic. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim, Bayer, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To reduce toxicity of geldanamycin (GDM), the domino transformation of its benzoquinone core into benzoxazole has been performed. Structural studies of ester-phenol and ester-ether benzoxazole-type ansamycins indicate that the former is present as (Sp)-diastereomer, whereas the latter is present as conformation-“locked” (Rp)-diastereomer, which is more favorable at binding to Hsp90. Several of the obtained benzoxazole ansamycins revealed high anticancer potency in SKBr-3, MCF-7, SKOV-3, and PC-3 lines with improved selectivity and lower affinity to glutathione, compared to GDM. The most potent derivative 6 reveals excellent anticancer activity (IC50 < 0.6 μM) with Hsp90 as the primary target [KD6-Hsp90 = 0.3 μM], limited off-target effects (kinases), and decreased toxicity (selectivity indices = 2.75−3.48) regarding GDM. Ester-ether type derivative 22 reveals good anticancer potency in SKOV-3 (IC50 = 0.62 μM) with reduced toxicity in human dermal fibroblast and human umbilical vein endothelial cells, improved selectivity (SISKOV-3 = 2.75), apoptotic index AISKOV-3 ∼8, and high chemical and in vivo stabilities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HSP90 Heat-Shock ProteinsAntineoplastic AgentsBenzoxazolesLactams, MacrocyclicHumansStereoisomerismStructure-Activity RelationshipCell Line, TumorBenzoquinonesDrug Screening Assays, Antitumor

Stichwörter der Autor:innen

apoptotic indicesatropisomerscytotoxicitydissociation constantsgeldanamycinkinases

Substanzen

HSP90 Heat-Shock ProteinsAntineoplastic AgentsBenzoxazolesBenzoquinonesLactams, Macrocyclicgeldanamycin

Autor:innen und Institutionen

  • Faculty of Chemistry, Adam Mickiewicz University, Uniwersytetu Poznanskiego 8, 61-614Poznan, Poland.
  • Department of Physical Chemistry, Faculty of Chemistry, University of Lodz, Pomorska 163/165, Lodz90-236, Poland.
  • Department of Pharmacology, Poznan University of Medical Sciences, Rokietnicka 5a, 60-806Poznań, Poland.
  • Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina27599, United States.
  • Institute of Organic Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224Warsaw, Poland.
  • Lebenswissenschaftliche Fakultӓt, Institut fȕr Biologie, Biophysikalische Chemie, Humboldt-Universitӓt zu Berlin, Invalidenstraße 42, 10115Berlin, Germany.

ORCID-Profile: Aleksandra Leśniewska, Adam Buczkowski, Matthew J Binder, Alison D Axtman, Ewelina Smolarz, Krystian Pyta, Maria Gdaniec, Piotr Przybylski

Förderung

  • Boehringer Ingelheim
  • Bayer
  • Pfizer
  • Genome Canada
  • Genentech
  • Merck KGaA
  • Eshelman Innovation
  • Takeda Canada

Zitieren

APA

Leśniewska, A., Buczkowski, A., Ruszkowski, P., Binder, M. J., Axtman, A. D., Schilf, W., Smolarz, E., Pyta, K., Gdaniec, M., Bartl, F. J., & Przybylski, P. (2026). Cascade Mono- and Di-Functionalization of Anticancer Diastereomeric Benzoxazole-Ansamycins toward the Development of Highly Potent Hsp90 Inhibitors of Decreased Toxicity in Normal Cells. Journal of Medicinal Chemistry, 69(21), 25151-25180. https://doi.org/10.1021/acs.jmedchem.6c00563

Vancouver

Leśniewska A, Buczkowski A, Ruszkowski P, Binder MJ, Axtman AD, Schilf W, et al. Cascade Mono- and Di-Functionalization of Anticancer Diastereomeric Benzoxazole-Ansamycins toward the Development of Highly Potent Hsp90 Inhibitors of Decreased Toxicity in Normal Cells. Journal of Medicinal Chemistry. 2026;69(21):25151-25180. doi:10.1021/acs.jmedchem.6c00563

BibTeX
@article{Leniewska2026,
  author = {Leśniewska, Aleksandra and Buczkowski, Adam and Ruszkowski, Piotr and Binder, Matthew J and Axtman, Alison D and Schilf, Wojciech and Smolarz, Ewelina and Pyta, Krystian and Gdaniec, Maria and Bartl, Franz J and Przybylski, Piotr},
  title = {Cascade Mono- and Di-Functionalization of Anticancer Diastereomeric Benzoxazole-Ansamycins toward the Development of Highly Potent Hsp90 Inhibitors of Decreased Toxicity in Normal Cells},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {21},
  pages = {25151--25180},
  doi = {10.1021/acs.jmedchem.6c00563}
}
Kostenlos starten →